Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020

Acasti Pharma, Inc. - Class A (ACST)
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acastipharma.com/investors
Company Research
Source: GlobeNewswire
Achieved 100% Patient Randomization in both TRILOGY trials 68% of randomized patients have completed the studies On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020 Fully funded beyond completion of Phase 3 studies Approximately $8.1 million in additional proceeds from exercise of warrants since July 1, 2019 Acasti management to host conference call at 1 PM ET today LAVAL, Québec, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the first quarter of fiscal 2020 ended June 30, 2019. All amounts are in Canadian dollars. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Our TRI
Show less
Read more
Impact Snapshot
Event Time:
ACST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACST alerts
High impacting Acasti Pharma, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ACST
News
- Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023PR Newswire
- Share this Story: Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price RuleGlobeNewswire
- Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 [Canadian Business Journal (Canada)]Canadian Business Journal
- Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31GlobeNewswire
ACST
Earnings
- 2/14/22 - Miss
ACST
Sec Filings
- 1/25/23 - Form 8-K
- 12/28/22 - Form 8-K
- 12/22/22 - Form 8-K
- ACST's page on the SEC website